MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Clinical Updates
Clinical Updates

Subcutaneous Blinatumomab in Relapsed/Refractory B-ALL: Clinical Promise and the Future of Delivery Modalities

MedXY Editorial TeamAug 2, 2025
B-cell ALLblinatumomabimmunotherapysubcutaneous administration

Highlights

  • Subcutaneous blinatumomab achieved high remission rates (75-79%) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
  • Both evaluated dosing regimens exhibited manageable safety profiles, with primary toxicities consistent with known blinatumomab effects.
  • The 250 μg/500 μg subcutaneous regimen was selected as the recommended phase 2 dose due to balanced efficacy and tolerability.
  • Subcutaneous administration offers logistical and potentially economic advantages that may drive a future trend in immunotherapy delivery.

Clinical Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story